An investing entry point for Advanced Oncotherapy (AVO)?

An investing entry point for Advanced Oncotherapy (AVO)? Alan Green discusses on TipTV. Click below.


In a bananas market is Fyffes (FFY) the company to hold?

FyffesIn a bananas market is this the company to hold? Alan Green discusses the case for Fyffes (FFY) with Justin Waite on the ADVFN podcast. Click here to listen to the podcast.


Updated Thurs Aug 27, cracking first half numbers from Fyffes (FFY) reports H1 EBITDA up 12.4% to €39.5m on total revenues up 8.7% to €644.3m. The interim dividend rises 15% to 0.82c and the group reconfirms full year targets of adjusted EBITDA between €55m – €61m.

Advanced Oncotherapy – Broker Notes

AVO1Advanced Oncotherapy

Broker Notes

Westhouse retains a Buy recommendation with a Target Price of 25p.

Advanced Oncotherapy (AVO) – Analyst Robert Sanders – On Schedule. Two CCL modules are announced as ready for high-power testing. This is the first time two CCL modules will be tested together…the finished proton beam cancer treatment machine (LIGHT system) will incorporate 10 CCL units/15 CCL modules in a series so that protons are accelerated to the necessary speed to treat radiosensitive tumours. AVO has to date been hitting all of its previously set-out milestones. Westhouse Securities said in a note growing awareness of proton therapy as a treatment for cancer should ensure strong demand for Advanced Oncotherapy’s LIGHT system. Analyst Robert Sanders said Monday’s news showed the company was on track to have its treatment on track for 2017.

Beaufort Securities has a Speculative Buy rating.

Says the High-power testing of LIGHT’s individual components and modules at this stage is a crucial demonstration of their ability to perform to specifications. Initial low power testing has shown that they perform to expectations and it is realistic to expect that the successful conclusion of these tests to build confidence that the CCL modules can work under the required conditions to deliver the high energy protons required to treat patients effectively. Results from this work should be expected during Q4’15, before moving onto to running the modules in series as a bank of accelerators. Once demonstrated, the most significant technological hurdle will have been successfully negotiated, leaving only a number of less challenging barriers ahead. While Beaufort considers that the FDA could potentially hinder product approval for rather longer than might presently be anticipated, the extent of interest from other non-dependent territories (in particular that presently being shown from China) suggests the Group is likely to be overwhelmed by demand for LIGHT as soon as commercial units become available. The enormity of this opportunity and the market potential it presents has already been significantly detailed in Beaufort initiation research of September 2014 and subsequent updates. In simple terms, if AVO delivers exactly ‘what it says on the tin’, the operational and cost advantages LIGHT offers will effectively render first generation proton therapy devices all but obsolete. Its principal limitation would then become simply its capacity to deliver to a global opportunity that will grow dramatically beyond its current US$2.5bn size, as it will also become the natural replacement for the more antiquated X-ray radiation machines that are installed in huge numbers around the globe. Given such an outcome, of course, major international competitors wishing to remain in the game will almost certainly be willing to pay a handsome price, one way or another, to get their hands on AVO’s proprietary technologies. Advanced Oncotherapy plc remains one of Beaufort’s key investment picks for 2015. Beaufort Securities acts as corporate broker to Advanced Oncotherapy plc

Daily Telegraph – Shares in Advanced Oncotherapy jump amid chatter of Chinese contract win

AVO1By Tara Cunningham, Business Reporter, Daily Telegraph:

As global equity markets faltered last week, Advanced Oncotherapy bucked the trend amid chatter of a contract win in China. Speculation Advanced Oncotherapy, the developer of next-generation proton therapy systems for cancer treatment, secured a second contract in China drove the share price higher last week.
While global equity markets faltered, the Aim-listed company bucked the trend rising by as much 8.8% to 7.5p after chatter emerged its partner for the Chinese market, Sinophi Healthcare, had recently signed a contract with China-Japan Union Hospital of Jilin University, in Changchun, to build a proton therapy centre.

However, the company was quick to dispel rumours it had won another contract for a LIGHT system – its proton beam therapy machine. In a statement, management said “should a purchase order be received, shareholders will be notified”

Full article here

Call This A Crash ? – Remember 1974

The present sharp falls in world stock markets don’t even count as a minor bump, never mind a crash, compared to the collapse of 1973-74, when The London Stock Market lost 73% of its value in less than two years. From a peak of over 700 it fell to well under 200, with genuine fears that it was going to break the 100 barrier.

The fact that it did not, was due entirely to the actions of one company, Britains largest manufacturing company, Imperial Chemical Industries which then bestrode the world like a colossus and had a huge pension fund. Without warning ICI pension fund started buying shares, ( if I remember correctly in December 1974) and did so on such a scale that on its own it turned the index, which began to recover and in 1975 rose by a huge 150%.

But it was a close run thing. A huge boom in UK property prices had come apart leading to the collapse or near collapse of many secondary banks, forcing the government, not for the last time, to step in and start bailing out  banks to save the banking system.

In the USA things were not much better. Between the 11th January 1973 and the 6th December 1974, the DOW lost 45% of its value in the worlds 7th worst bear market. The US economy slowed from growth of 7.2% to a fall of 2.1% and inflation more than tripled, reaching 12.3% in 1974.

In the UK it took more than 13 years for UK stocks to return to their pre 1973 levels and then they were hit by the original Black Monday. In real terms the recovery took 19 years.

So if the present “crisis” is to become a true bear market,which requires a fall of 20% in stock markets, it has a long way to go and shares have much, much further to fall.

Looking for villas and houses for sale in Greece – click here –

CEB Resources – Result of AGM

CEB ResourcesCEB Resources Plc is pleased to announce that at its Annual General Meeting held today all resolutions proposed were passed.

For further information:

CEB Resources Plc

Cameron Pearce / David Whitby

01624 681 250

Sanlam Securities UK Limited

Lindsay Mair

020 7628 2200

Peterhouse Corporate Finance Limited

Lucy Williams / Charles Goodfellow

Advanced Oncotherapy – CCL modules ready for high-power testing

AVO1Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that the two Coupled Cavity Linac modules are now ready for high-power testing at the Company’s facility in Geneva.

These two modules will be tested at high power by using the Radio Frequency Power Units provided by ScandiNova and Toshiba and it is the first time two CCL modules will be tested together. The finished LIGHT system will incorporate ten CCL units (15 CCL modules) in total and combined in a series will accelerate protons to the high energies required to treat radiosensitive tumours in a clinical setting.

Ensuring that the CCL units were ready for high-power testing was a key milestone in the Company’s timetable provided to shareholders in November 2014, and this marks another successful stage in the process of delivering the first working LIGHT system.

Commenting, Sanjeev Pandya, CEO of Advanced Oncotherapy, said: “The high-power testing of the components at this stage will be a crucial demonstration of their ability to perform to specifications. Initial low power testing has shown that they perform to expectations and we expect that the successful conclusion of these tests will give us confidence that the CCL modules can work under the required conditions to deliver the high energy protons that we need to treat patients effectively.”

Advanced Oncotherapy Plc

Sanjeev Pandya, CEO

Tel: +44 20 3617 8728

Nicolas Serandour, CFO

Westhouse Securities (Nomad & Joint Broker)

Antonio Bossi / David Coaten

Tel: +44 20 7601 6100

Beaufort Securities (Joint Broker)

Jon Levinson / Zoe Alexander

Tel: +44 20 7382 8300

Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or

Paul McManus / Anna Dunphy

Mob: +44 7980 541 893 / Mob: +44 7876 741 001

Alan Green discusses mini Hargreaves Lansdown, Mattioli Woods (MTW) on the ADVFN podcast

Alan Green discusses Mattioli Woods (MTW), a mini Hargreaves Lansdown (HL.) on the ADVFN podcast with Justin Waite. Click here to listen to the podcast.

Special offer to our readers – 25% discount on RRP on Share Attack

ShareAttack80 Great Tips to survive and thrive as a Trader

Published by Harriman House, Share Attack is the latest book from share author and former BBC journalist Malcolm Stacey.

Simply click on the cover image to go to the Harriman House website for more info.


Our readers can take advantage of a unique offer from us. Order Share Attack and enter the following codes to receive 25% discount from RRP.

SHAREATTACK25PB – for the paperback here
SHAREATTACK25EB – for the eBook here

Alan Green discusses the latest Quindell (QPP) developments on TipTV

Alan Green discusses the latest Quindell (QPP) developments with Zak Mir on TipTV. Click to watch